Amplia's CEO & MD, Dr Chris Burns, spoke with Andrew Scott at Proactive about the Company's upcoming research collaboration with CSIRO to investigate the development of topical formulations of its FAK inhibitors to aid wound healing and reduce scarring.
Watch it here.
